| 目錄號 | MZ4001-1G | 售價 | 890.00元 | ||||||||||||||||||||||||||||||||||||||||||||
| 規格 | 1g | 運輸溫度 | 室溫運輸 | ||||||||||||||||||||||||||||||||||||||||||||
| 其他名稱 | 保存溫度 | 2-8℃干燥保存 | |||||||||||||||||||||||||||||||||||||||||||||
| CAS號 | 2353-33-5 | 有效期 | 或置于-20℃長期干燥保存，至少3年有效。 | ||||||||||||||||||||||||||||||||||||||||||||
| 應用 | 訂購數量 |
|
|||||||||||||||||||||||||||||||||||||||||||||
|
產品簡介: Decitabine (5-aza-2'-deoxycytidine) 地西他濱(5-氮雜-2′-脫氧胞苷)
產品信息
產品描述 地西他濱（Decitabine），又稱為5-氮雜-2′-脫氧胞苷（5-Aza-2′-deoxycytidine），一種胞嘧啶類似物，一旦插入DNA后，可用作DNA甲基轉移酶的一種自殺性底物。能抑制DNA甲基轉移酶活性，引起DNA低甲基化和沉默基因的活化。地西他濱是一種化療劑，可抑制人腫瘤細胞系的生長。還能去甲基分化相關基因。逆轉胚胎干細胞分化。
產品特性 1） CAS NO：2353-33-5 2） 化學名：4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one 3） 英文同義名：2'-Deoxy-5-azacytidine, 5-Aza-2'-deoxycytidine, Deoxycytidine, NSC 127716, 5AZA-CdR 4） 中文同義名：2'-脫氧-5-氮雜胞苷；5-氮雜-2′-脫氧胞苷；脫氧胞苷； 5） 分子式：C8H12N4O4 6） 分子量：228.21 7） 純度：≥99%(HPLC) 8） 外觀：白色或類白色結晶性粉末 9） 溶解性：溶于DMSO（~45 mg/ml），略溶于水（~10mg/ml），幾乎不溶于乙醇
10） 化學結構圖：
保存與運輸方法 保存：2-8℃干燥保存，或置于-20℃長期干燥保存，至少3年有效。 運輸：室溫運輸
注意事項 1） 地西他濱遇水會迅速降解，建議用有機溶劑如DMSO來配制母液，置于-20℃分裝保存，至少3個月穩定。若需要用水或水溶性緩沖液來配制母液，請現配現用，且盡快用完，不建議做保存。 2） 本品本身并非完全無菌的，若需要無菌溶液且用水或水溶性緩沖液來溶解粉末，需過濾除菌后再使用。 3） 本品僅用作科研用途，不得用作臨床診斷或治療，不得用于食品或藥品，絕對禁止用在人身上。 4） 為了您的安全和健康，請穿實驗服并戴一次性手套操作。
配制儲存液
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
文獻1，Maes K et al.The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Oncotarget. 2014 May 30;5(10):3115-29. PMID: 24833108 體外研究： 樣本類型（Sample type）：Human myeloma cell lines (HMCLs)(OPM-2, NCI-H929, RPMI-8226 and JJN3 cells) 藥物配制（Preparation）：Decitabine (Dacogen) was dissolved in dimethylsulfoxide. 實驗方法（Assay）：HMCLs were treated with different concentrations of decitabine (DAC) for indicated timepoints. Apoptosis was determined by flow cytometry using AnnexinV-FITC/7'AAD staining. 實驗結果（Results）：OPM-2 and NCI-H929 cells showed significant induction of apoptosis from 3 days on, while RPMI-8226 and JJN3 cells were more sensitive showing increased apoptosis already after 2 days. 體內研究： 動物模型（Animal Model）：5T33MM mice 藥物配制（Preparation）：For in vivo experiments, decitabine was used as a filter sterilized 10% hydroxypropyl- cyclodextran suspension. 實驗方法（Assay）：At day 0, naive C57BL/KaLwRij mice were intravenously injected with 5×1055T33MM cells. Mice were treated with decitabine starting at day 1 (intraperitoneal injection, 6 days/week). Treatment groups were vehicle (n=9), 0.2 (n=9) and 0.5mpk decitabine (n=9). Mice were sacrificed individually when showing signs of morbidity. 實驗結果（Results）：Tumor load in the BM and serum M-spike were significantly lower for all decitabine treatment groups. 5T33MM mice treated with decitabine had significant higher survival rates when compared to vehicle treated mice: 29 and 36 days for respectively 0.2mg/kg decitabine and 0.5mg/kg decitabine versus 25 days for vehicles. |
|
文獻2，Terse P et al. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol. 2014 Mar-Apr;33(2):75-85. PMID: 24639139 體內研究： 動物模型（Animal Model）：CD-1 mice (male 30-38 g and female 24-31g) 藥物配制（Preparation）：For Group 1 (DAC vehicle), a 5% solution of potassium phosphate buffer in sodium chloride for injection (SCFI) was prepared; for Groups 2 to 5, a 2 mg/mL stock solution of DAC was prepared by adding the appropriate amount of DAC to the potassium phosphate buffer; the pH was adjusted to 6.90 ± 2.90%). The dosing formulations of DAC (0.02, 0.04, and 0.1 mg/mL) were prepared by diluting the 2 mg/mL stock solution with SCFI. 實驗方法（Assay）：Animals were gavaged with DAC or its vehicle 1 hour ± 5 minutes after administration of THU or its vehicle at a dose volume of 10 mL/kg. |
— —Written/Edited by V. Shallan【版權歸MKBio懋康所有】
上海懋康生物科技有限公司是一家涉足于生命科學和生物技術領域研究的試劑、儀器和實驗室消耗品與實驗服務工作，主要從事細胞生物學、植物學、分子生物學、免疫學、生物化學、蛋白組學。生物制藥與診斷試劑研發生產等領域。 本公司秉承“以人為本，以誠為信、合同守信”的經營理念。堅持"品質保障"的原則為廣大客戶提供優質產品。
